T1	Participants 125 184	in patients with mixed dyslipidaemia and metabolic syndrome
T2	Participants 377 406	the metabolic syndrome (MetS)
T3	Participants 584 629	in patients with mixed dyslipidaemia and MetS
T4	Participants 653 927	randomised patients with low-density lipoprotein cholesterol (LDL-C) > 160 and TG > 200 mg/dl to rosuvastatin monotherapy 40 mg/day (R group, n = 30) or rosuvastatin 10 mg/day combined with fenofibrate 200 mg/day (RF group, n = 30) or ω-3 fatty acids 2 g/day (Rω group
T5	Participants 945 1054	present study, only patients with MetS were included (24, 23 and 24 in the R, RF and Rω groups respectively)
